GeneDx Holdings Corp.
NASDAQ:WGS · NASDAQ Global Market
+$1.52 today
Vol 0.66M · Avg 1.28M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$21.0M +59.8% | -$52.3M +70.3% | -$175.8M +68.0% | -$549.0M -123.7% | -$245.4M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $25.2M +14.9% | $22.0M -38.7% | $35.8M -39.6% | $59.3M +172.0% | $21.8M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 +100.0% | -$343.0K +63.0% | -$926.0K +98.1% | -$49.1M | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $32.2M +252.0% | $9.1M +2903.1% | -$326.0K -100.8% | $42.0M -80.9% | $219.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$15.6M +37.0% | -$24.7M +35.3% | -$38.2M -205.8% | $36.1M +347.3% | $8.1M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$36.2M -568.3% | -$5.4M -152.8% | $10.3M +85.7% | $5.5M -0.1% | $5.5M | $592.6M | $1.3B | $626.2M |
| Inventory | -$3.4M -32.9% | -$2.6M -365.1% | $975.0K -78.8% | $4.6M +143.3% | -$10.6M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $12.1M +159.1% | -$20.5M +56.4% | -$47.0M -236.3% | $34.5M | $0 | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $12.0M +221.6% | $3.7M +247.3% | -$2.5M +70.1% | -$8.5M -164.2% | $13.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $12.5M -29.7% | $17.8M +2567.0% | -$721.0K -100.5% | $141.5M +172.8% | -$194.3M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $33.3M +216.8% | -$28.5M +84.2% | -$180.1M +43.6% | -$319.2M -67.6% | -$190.4M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$19.0M -246.3% | -$5.5M +3.9% | -$5.7M +60.1% | -$14.3M +31.1% | -$20.8M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$32.9M | $0 +100.0% | -$8.1M +93.6% | -$127.0M | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$55.7M +16.0% | -$66.3M -39.1% | -$47.7M | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $46.0M +10.5% | $41.7M +134.5% | $17.8M | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 +100.0% | -$11.4M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$61.5M -104.2% | -$30.1M +31.1% | -$43.7M +69.1% | -$141.3M -579.9% | -$20.8M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$3.7M -13.6% | -$3.2M -107.5% | $43.0M +1404.7% | -$3.3M +75.6% | -$13.5M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $51.7M +11.2% | $46.5M -67.5% | $143.0M -27.7% | $197.7M -55.3% | $442.7M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $891.0K +212.6% | $285.0K -90.3% | $2.9M -95.4% | $64.5M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $48.0M +8.7% | $44.2M -76.3% | $186.2M -5.6% | $197.3M -60.0% | $493.7M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 +100.0% | -$87.0K | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $19.8M +236.8% | -$14.5M +61.7% | -$37.7M +85.7% | -$263.2M -193.2% | $282.5M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $14.3M +142.0% | -$34.0M +81.7% | -$185.9M +44.3% | -$333.5M -57.9% | -$211.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.43B
Oscar Health, Inc.
NYSE:OSCR
$7.30B
Immunovant, Inc.
NASDAQ:IMVT
$7.11B
Hinge Health, Inc.
NYSE:HNGE
$5.25B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.74B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.53B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.48B
Option Care Health, Inc.
NASDAQ:OPCH
$3.47B
Privia Health Group, Inc.
NASDAQ:PRVA
$2.97B
TransMedics Group, Inc.
NASDAQ:TMDX
$2.74B
SEC Filings
Recent regulatory filings
No filings found.
Does WGS generate free cash flow?
GeneDx Holdings Corp. (WGS) generated $14.26M of free cash flow in fiscal 2025.
How much operating cash flow does WGS produce?
Operating cash flow was $33.28M, before capital expenditures of $19.02M.
Explore More
Continue the stock analysis
Jump to another research area for this company.